CORT
Price
$82.64
Change
-$0.68 (-0.82%)
Updated
Sep 24, 11:53 AM (EDT)
Capitalization
8.78B
35 days until earnings call
ISCO
Price
$0.13
Change
-$0.01 (-7.14%)
Updated
Sep 22 closing price
Capitalization
1.04M
Interact to see
Advertisement

CORT vs ISCO

Header iconCORT vs ISCO Comparison
Open Charts CORT vs ISCOBanner chart's image
Corcept Therapeutics
Price$82.64
Change-$0.68 (-0.82%)
Volume$318
Capitalization8.78B
International Stem Cell
Price$0.13
Change-$0.01 (-7.14%)
Volume$1.82K
Capitalization1.04M
CORT vs ISCO Comparison Chart in %
Loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CORT vs. ISCO commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Buy and ISCO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (CORT: $83.32 vs. ISCO: $0.13)
Brand notoriety: CORT and ISCO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 112% vs. ISCO: 34%
Market capitalization -- CORT: $8.78B vs. ISCO: $1.04M
CORT [@Biotechnology] is valued at $8.78B. ISCO’s [@Biotechnology] market capitalization is $1.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 1 FA rating(s) are green whileISCO’s FA Score has 1 green FA rating(s).

  • CORT’s FA Score: 1 green, 4 red.
  • ISCO’s FA Score: 1 green, 4 red.
According to our system of comparison, CORT is a better buy in the long-term than ISCO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 5 TA indicator(s) are bullish while ISCO’s TA Score has 1 bullish TA indicator(s).

  • CORT’s TA Score: 5 bullish, 5 bearish.
  • ISCO’s TA Score: 1 bullish, 5 bearish.
According to our system of comparison, CORT is a better buy in the short-term than ISCO.

Price Growth

CORT (@Biotechnology) experienced а +16.83% price change this week, while ISCO (@Biotechnology) price change was -0.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.34%. For the same industry, the average monthly price growth was +10.13%, and the average quarterly price growth was +53.93%.

Reported Earning Dates

CORT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+4.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($8.78B) has a higher market cap than ISCO($1.04M). CORT YTD gains are higher at: 65.350 vs. ISCO (59.902). CORT has higher annual earnings (EBITDA): 104M vs. ISCO (128K). CORT has more cash in the bank: 342M vs. ISCO (920K). ISCO has less debt than CORT: ISCO (3.85M) vs CORT (6.61M). CORT has higher revenues than ISCO: CORT (716M) vs ISCO (9.2M).
CORTISCOCORT / ISCO
Capitalization8.78B1.04M843,420%
EBITDA104M128K81,250%
Gain YTD65.35059.902109%
P/E Ratio74.39N/A-
Revenue716M9.2M7,782%
Total Cash342M920K37,174%
Total Debt6.61M3.85M172%
FUNDAMENTALS RATINGS
CORT vs ISCO: Fundamental Ratings
CORT
ISCO
OUTLOOK RATING
1..100
1923
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
35100
SMR RATING
1..100
43100
PRICE GROWTH RATING
1..100
4155
P/E GROWTH RATING
1..100
1085
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is significantly better than the same rating for CORT (83) in the Pharmaceuticals Other industry. This means that ISCO’s stock grew significantly faster than CORT’s over the last 12 months.

CORT's Profit vs Risk Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for ISCO (100) in the null industry. This means that CORT’s stock grew somewhat faster than ISCO’s over the last 12 months.

CORT's SMR Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for ISCO (100) in the null industry. This means that CORT’s stock grew somewhat faster than ISCO’s over the last 12 months.

CORT's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as ISCO (55) in the null industry. This means that CORT’s stock grew similarly to ISCO’s over the last 12 months.

CORT's P/E Growth Rating (10) in the Pharmaceuticals Other industry is significantly better than the same rating for ISCO (85) in the null industry. This means that CORT’s stock grew significantly faster than ISCO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTISCO
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
66%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
40%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ISCO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
URE64.550.89
+1.40%
ProShares Ultra Real Estate
MANA2.15N/A
+0.19%
Grayscale Decentraland Trust (MANA)
FCFY27.32N/A
N/A
First Trust S&P 500 Div Fr CA Flw ETF
GAL49.35-0.09
-0.19%
SPDR® SSgA Global Allocation ETF
VTWG236.80-1.05
-0.44%
Vanguard Russell 2000 Growth ETF

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with VTVT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then VTVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
+4.15%
VTVT - CORT
48%
Loosely correlated
-0.75%
DNLI - CORT
40%
Loosely correlated
-2.03%
TENX - CORT
38%
Loosely correlated
+1.56%
ARCT - CORT
38%
Loosely correlated
-3.66%
HNSBF - CORT
38%
Loosely correlated
N/A
More

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and XBIT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and XBIT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
N/A
XBIT - ISCO
29%
Poorly correlated
+5.82%
INDP - ISCO
22%
Poorly correlated
+9.51%
CORT - ISCO
21%
Poorly correlated
+4.15%
BLTE - ISCO
20%
Poorly correlated
-0.34%
IVBXF - ISCO
5%
Poorly correlated
-3.20%
More